Summary & Overview
CPT 0602U: Diabetes Risk Test — Genetic and Metabolic Analysis
CPT code 0602U identifies the Kihealth Inc® Diabetes Risk Test, a proprietary laboratory assay that integrates genetic methylation analysis of the insulin (INS) gene with immunoassay measurements of insulin, C–peptide, and hemoglobin A1c to produce a diabetes‑risk score. As a PLA code, 0602U is specific to a single manufacturer's test and signals the presence of a combined molecular and metabolic diagnostic intended to stratify diabetes risk. Nationally, PLA codes like 0602U matter because they enable payer systems to recognize and track utilization of unique, manufacturer‑specific laboratory tests as precision diagnostics expand.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for this combined genetic/metabolic test, the typical service delivery setting, and the implications of PLA designation for coverage and billing workflows. The publication summarizes benchmark considerations, common payer coverage pathways for proprietary laboratory tests, and policy factors that influence reimbursement and coding recognition for novel diagnostic algorithms. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0602U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Kihealth Inc® Diabetes Risk Test performed by Kihealth Inc® Laboratory. The test combines genetic and metabolic measurements to generate a diabetes-risk score using a proprietary algorithm. It analyzes INS gene methylation via digital droplet polymerase chain reaction (ddPCR) and measures insulin, C–peptide, and hemoglobin A1c using immunoassay methods.
Service Type: Laboratory test combining molecular (ddPCR methylation analysis) and immunoassay-based metabolic biomarker measurement with algorithmic risk scoring.
Typical Site of Service: Clinical laboratory or reference diagnostic laboratory (specimen collected in an outpatient or ambulatory setting and sent to the performing laboratory for analysis).
Clinical & Coding Specifications
Clinical Context
A 45-year-old adult with a family history of type 2 diabetes and features of metabolic syndrome (overweight, fasting hyperglycemia, or impaired glucose tolerance) presents to a primary care clinic or endocrine specialty practice requesting more refined risk stratification for future diabetes. The clinician orders the Kihealth Inc® Diabetes Risk Test (0602U), a proprietary laboratory analysis performed at Kihealth Inc® Laboratory. A blood draw is obtained in an outpatient laboratory or clinic phlebotomy area; samples are sent to the manufacturer’s laboratory for processing. The laboratory performs digital droplet PCR to assess insulin (INS) gene methylation and immunoassays for insulin, C‑peptide, and hemoglobin A1c, then applies a proprietary algorithm to generate a diabetes‑risk score. Results are reported back to the ordering provider, who reviews the score alongside clinical data (history, BMI, fasting glucose, A1c, lipid profile) to inform counseling and surveillance frequency. Typical sites of service include outpatient primary care clinics, endocrinology clinics, ambulatory laboratory centers, and commercial reference laboratories. Typical service type: Proprietary Laboratory Analysis (PLA) — specialized diagnostic laboratory test performed by a single manufacturer/laboratory.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use if billing separately for the professional interpretation component when applicable and allowed by policy. |
TC | Technical component | Use when billing only the technical component of the laboratory test, where permitted. |
59 | Distinct procedural service | Use when this laboratory procedure is distinct from other services billed the same day and payer requires separation. |
90 | Reference (outside) laboratory | Use when the test is performed by a laboratory other than the billing laboratory. |
91 | Repeat clinical diagnostic laboratory test | Use when the exact same test is repeated on the same day for monitoring or verification per payer rules. |
52 | Reduced services | Use if the full service was not performed and payer allows reduced reporting. |
24 | Unrelated E/M service by same physician or other qualified health professional during a postoperative period | Use when an unrelated E/M visit occurs during a global period while the lab test is billed separately. |
25 | Significant, separately identifiable E/M service on the same day | Use when an E/M is reported in addition to the test and meets documentation requirements. |
QW | CLIA waived test (historically) | Not typically applicable to PLA tests like 0602U; include only if payer-specific guidance indicates. |
GA | Waiver of liability statement on file | Use when patient has signed ABN or similar and payer requires this modifier per local rules. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207Q00000X | Family Medicine | Primary care clinicians who order risk stratification tests for metabolic disease. |
| 207RE0101X | Endocrinology | Specialists managing diabetes risk and interpreting advanced metabolic markers. |
| 207L00000X | Internal Medicine | Hospital‑based and outpatient internists who manage prediabetes and order specialized labs. |
| 363LP0808X | Clinical Laboratory | Laboratory professionals and diagnostic service providers responsible for performing and reporting the PLA. |
| 208D00000X | Diagnostic Radiology (not typical) | Data not typically applicable; included only if a diagnostic practice coordinates testing — otherwise may be omitted. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
E11.9 | Type 2 diabetes mellitus without complications | Common diagnosis relevant to risk stratification and monitoring; PLA results may inform management in patients with established type 2 diabetes. |
R73.03 | Prediabetes | Directly relevant: patients with impaired glucose tolerance or elevated fasting glucose often undergo additional risk assessment. |
E66.9 | Obesity, unspecified | Obesity is a major risk factor for type 2 diabetes; clinicians may order the test for risk assessment in patients with obesity. |
Z13.1 | Encounter for screening for diabetes mellitus | Used when the test is ordered as part of screening or risk assessment in asymptomatic individuals. |
Z82.1 | Family history of diabetes mellitus | Family history increases lifetime risk; genetic and epigenetic markers in the PLA are clinically relevant when family history is present. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0602U | Kihealth Inc® Diabetes Risk Test — proprietary analysis measuring INS gene methylation by ddPCR and immunoassay for insulin, C‑peptide, and hemoglobin A1c with algorithmic diabetes‑risk score | The primary PLA code that identifies this manufacturer‑specific laboratory test; used when the test is performed by Kihealth Inc® Laboratory. |
83036 | Hemoglobin; glycosylated (A1c) | Common laboratory assay for diabetes screening and monitoring; A1c is measured within the proprietary panel and would otherwise be reported with this standalone code if performed outside the PLA. |
82550 | Drug assay, presumptive, any number of drug classes; qualitative | Not directly related clinically but represents standardized reporting for immunoassays when separate toxicology testing is performed in parallel. |
83037 | Hemoglobin; glycosylated (A1c) by device cleared by the FDA for home use (e.g., point of care) | Relevant when point‑of‑care A1c is performed in clinic in addition to or prior to sending the PLA to the reference lab. |
0000U | Proprietary Laboratory Analyses (example PLA placeholder) | Represents the class of PLA codes; included to indicate that 0602U is a PLA and that other PLA codes may be used for different manufacturer tests. |